Latvenergo AS implements placement of notes under the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Latvenergo AS implements placement of notes under the second series of notes

Riga, 2013-09-27 11:13 CEST (GLOBE NEWSWIRE) -- On 26 September 2013 Latvenergo AS (Baa3/stable, Moody`s) implemented placement of notes in the total nominal value of EUR 15 million under the second series of notes.

The public announcement was made in the Republic of Latvia, in the Republic of Lithuania and in the Republic of Estonia. The yield to maturity range was determined from SW* +1.70% to SW +2.00%. The total amount of the submitted purchase orders had reached EUR 24.04 million. The purchase orders were received from different investors - pension funds, asset management funds, insurance companies and banks in Latvia, Lithuania and Estonia.

The terms of the additional issue of the second series of notes are the following:

Serial number of series of notes: 2 Principal amount of the additional issue: EUR 15,000,000 Amount of the additional notes: 15,000 Nominal amount of the note: EUR 1,000 Annual interest rate (coupon): fixed, 2.8% Issue price: EUR 971,665 Final yield to maturity: 3.458% Issue date: 2 October 2013 Maturity date: 22 May 2020

Aggregate principal amount of the series of notes: EUR 35,000,000

In accordance with the Final Terms of the additional issue of the second series of notes temporary ISIN code is LV0010801163. Upon admission of the notes to the regulated market the notes will be consolidated and form a single series with the notes in the amount of EUR 20,000,000 issued on 22 May 2013 and will have a common ISIN code LV0000801165.

The issue of notes is being implemented under Latvenergo AS LVL 85 million (or its equivalent in EUR) programme for the issuance of notes. The arranger of the issue of notes – SEB banka AS.

The issue of notes is realized within the Latvenergo Group borrowing plans and the net proceeds from the issue of the notes will be used for financing Latvenergo Group`s capital expenditures programme, including but not limited to financing of renewal of transmission and distribution lines, reconstruction of transformer substations, investments in voltage quality improvement, as well as replacement of overhead lines with cable lines to improve the quality and reliability of electricity supply to customers and to reduce the network losses.

* an interpolated interest rate swap derived from a six-year interest rate swap and a seven-year interest rate swap

Additional information : J?nis Irbe Group Treasurer Phone: +371 67 728 239 E-mail: investor.relations@latvenergo.lv

www.latvenergo.lv/investors/eng

About Latvenergo

Latvenergo Group is a pan-Baltic energy company, engaging in electricity and thermal energy generation and supply, electricity distribution services and management of transmission system assets. Latvenergo Group holds one-third of the entire Baltic electricity market, thus ensuring its leadership in the Baltic electricity supply. Latvenergo AS has been acknowledged as the most valuable company in Latvia for several years in a row. International credit rating agency Moody’s has assigned Latvenergo AS an investment-grade credit rating of Baa3/stable.

Latvenergo Group includes the parent company Latvenergo AS (electricity and thermal energy generation and supply) and its subsidiaries Latvijas elektriskie t?kli AS (management of transmission system assets), Sadales t?kls AS (electricity distribution), Elektrum Eesti OÜ (electricity  supply in Estonia), Elektrum Lietuva UAB (electricity  supply in Lithuania) and Liep?jas ener?ija SIA (thermal energy generation and supply, electricity generation), as well as Elektrum Latvija SIA (electricity supply), a subsidiary of Elektrum Eesti OÜ.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 11

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 7

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 7

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 11

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 4

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 10

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 6

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 10

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 5

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Chart Industries Transitions to New Leadership in Upcoming Merger

Updated Category News Views 231

Chart Industries Announces Leadership Change Chart Industries (NYSE: GTLS) is taking significant steps toward a future transition as CEO Jill Evanko has announced plans to assume a senior advisor role starting in early 2026. This change comes as she prepares to take on a new executive opportunity within a privately owned company. Evanko has been essential in steering the...

Continue Reading
Understanding Debtors: Insights into Realkredit Danmark A/S

Updated Category News Views 299

Understanding Debtors: Key Insights from Realkredit Danmark A/S At the heart of any effective financial institution is a reliable understanding of its debtors. Realkredit Danmark A/S, a prestigious name in the financial landscape, recently made available a detailed breakdown of its debtors. This information is crucial for various stakeholders, including investors,...

Continue Reading
Cryptocurrency Market Update: Bitcoin Droops under $59K with ETF Inflows Soaring

Updated Category News Views 148

Bitcoin's Recent Performance The cryptocurrency market has been lively lately, especially with Bitcoin recently falling below the $59,000 threshold. Investors had been optimistic, especially since the cryptocurrency saw a remarkable $436 million in net ETF inflows just last week. This significant influx signals that institutional interest in cryptocurrencies is still...

Continue Reading
Enhancing Specialized Care for ARFID Treatment with Emily Program

Updated Category News Views 169

Introduction to The Emily Program and ARFID The Emily Program is making significant strides in specialized care for individuals with Avoidant/Restrictive Food Intake Disorder (ARFID). This condition, often misunderstood, has recently begun to garner more attention from healthcare experts. In response to this need, The Emily Program is offering advanced treatment...

Continue Reading
Investigation of Alleged Securities Fraud at 3D Systems Unfolds

Updated Category News Views 167

Overview of Legal Actions Against 3D Systems Corporation Recently, investors in 3D Systems Corporation have found themselves entangled in a potential securities fraud lawsuit. This case serves as a cautionary tale, highlighting the importance of transparency and integrity in corporate communication. The allegations stem from assertions that the company made misleading...

Continue Reading